Table 2

Univariate analysis of the prognostic factors

VariableHazard ratio (95% CI)p value
Diagnosis, PPH v secondary PH1.22 (0.97 to 1.53)0.096
Treatment, PT vCT0.98 (0.79 to 1.21)0.816
Vasodilator response0.93 (0.73 to 1.18)0.555
NYHA (class III and IV)1.52 (1.11 to 2.09)0.009
Sex (male)1.07 (0.87 to 1.32)0.494
Age (/year increase)1.00 (0.98 to 1.02)0.900
Svo 2 (/% increase)0.97 (0.95 to 0.98)< 0.001
CO (/litre/min increase)0.77 (0.62 to 0.97)0.016
CI (/litre/min/m2)0.72 (0.49 to 1.06)0.082
mRAP (/mm Hg increase)1.04 (1.01 to 1.07)0.018
PVR (Wood units)1.02 (1.00 to 1.04)0.047
mPAP (/mm Hg increase)1.00 (0.99 to 1.01)0.763
  • Hazard ratio analysis using a univariate analysis. The p value is derived from the likelihood ratio test.

  • PT, prostaglandin treatment; CT, conventional treatment; CI, cardiac index; CO, cardiac output; mPAP, mean pulmonary artery pressure; mRAP mean right atrial pressure; NYHA, New York Heart Association grade; PPH, primary pulmonary hypertension; PVR, pulmonary vascular resistance; secondary PH, pulmonary hypertension secondary to systemic disease and thromboembolic disease; Svo 2, mixed venous oxygen saturation.